Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Growth in Short Interest

Key Points

• Short interest in Daiichi Sankyo has increased by 32.2%, reaching a total of 101,000 shares as of August 31, up from 76,400 shares on August 15.
• The company's stock currently has a market capitalization of $45.57 billion and trades at approximately $24.06 per share.
• Nomura Securities has upgraded Daiichi Sankyo to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 101,000 shares, an increase of 32.2% from the August 15th total of 76,400 shares. Based on an average daily volume of 611,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 611,300 shares, the short-interest ratio is presently 0.2 days.

Daiichi Sankyo Stock Performance

Shares of OTCMKTS:DSNKY traded down $0.73 during midday trading on Friday, hitting $23.96. The company had a trading volume of 102,441 shares, compared to its average volume of 187,032. Daiichi Sankyo has a 12-month low of $20.92 and a 12-month high of $35.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.85. The company has a market cap of $45.39 billion and a price-to-earnings ratio of 23.26. The company has a fifty day moving average of $24.47 and a two-hundred day moving average of $24.21.

Wall Street Analyst Weigh In

Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company has an average rating of "Strong Buy".

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.